# ![@NtRf7UTezCBvY5z Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1484714106980810752.png) @NtRf7UTezCBvY5z 快挙！FDA承認済メドレックスちのメドっちさん

快挙！FDA承認済メドレックスちのメドっちさん posts on X about  the most. They currently have [--] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: [--] [#](/creator/twitter::1484714106980810752/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1484714106980810752/c:line/m:interactions.svg)

- [--] Week [---] +4,000%

### Mentions: [--] [#](/creator/twitter::1484714106980810752/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1484714106980810752/c:line/m:posts_active.svg)

- [--] Week [--] +100%

### Followers: [--] [#](/creator/twitter::1484714106980810752/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1484714106980810752/c:line/m:followers.svg)


### CreatorRank: [---------] [#](/creator/twitter::1484714106980810752/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1484714106980810752/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks) 
### Top Social Posts
Top posts by engagements in the last [--] hours

"Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology # https://www.businesswire.com/news/home/20260113754206/en/Alto-Neuroscience-Presents-New-Data-at-the-64th-Annual-Meeting-of-the-American-College-of-Neuropsychopharmacology https://www.businesswire.com/news/home/20260113754206/en/Alto-Neuroscience-Presents-New-Data-at-the-64th-Annual-Meeting-of-the-American-College-of-Neuropsychopharmacology"  
[X Link](https://x.com/NtRf7UTezCBvY5z/status/2012421899507392557)  2026-01-17T07:09Z [--] followers, [---] engagements


"Alto Neuroscience Announces Completion of Enrollment in Phase [--] Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia # https://www.businesswire.com/news/home/20260213343048/en/Alto-Neuroscience-Announces-Completion-of-Enrollment-in-Phase-2-Proof-of-Concept-Study-of-ALTO-101-in-Cognitive-Impairment-Associated-with-Schizophreniautm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork"  
[X Link](https://x.com/NtRf7UTezCBvY5z/status/2022308597041127722)  2026-02-13T13:55Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing